PE20000339A1 - BICYCLE [2.2.1] HEPTANS AND RELATED COMPOUNDS - Google Patents
BICYCLE [2.2.1] HEPTANS AND RELATED COMPOUNDSInfo
- Publication number
- PE20000339A1 PE20000339A1 PE1999000198A PE00019899A PE20000339A1 PE 20000339 A1 PE20000339 A1 PE 20000339A1 PE 1999000198 A PE1999000198 A PE 1999000198A PE 00019899 A PE00019899 A PE 00019899A PE 20000339 A1 PE20000339 A1 PE 20000339A1
- Authority
- PE
- Peru
- Prior art keywords
- bicycle
- compound
- phenalflopramine
- exo
- serotonin
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- RTHCYVBBDHJXIQ-UHFFFAOYSA-N N-methyl-3-phenyl-3-[4-(trifluoromethyl)phenoxy]propan-1-amine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-UHFFFAOYSA-N 0.000 abstract 1
- 208000012902 Nervous system disease Diseases 0.000 abstract 1
- 208000025966 Neurological disease Diseases 0.000 abstract 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 abstract 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 1
- 239000011230 binding agent Substances 0.000 abstract 1
- 125000000816 ethylene group Chemical group [H]C([H])([*:1])C([H])([H])[*:2] 0.000 abstract 1
- 229960002464 fluoxetine Drugs 0.000 abstract 1
- 229960004038 fluvoxamine Drugs 0.000 abstract 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 229960002296 paroxetine Drugs 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 229940076279 serotonin Drugs 0.000 abstract 1
- 229960002073 sertraline Drugs 0.000 abstract 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/46—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton
- C07C229/50—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino or carboxyl groups bound to carbon atoms of rings other than six-membered aromatic rings of the same carbon skeleton with amino groups and carboxyl groups bound to carbon atoms being part of the same condensed ring system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/06—Antimigraine agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/08—Vasodilators for multiple indications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychology (AREA)
- Urology & Nephrology (AREA)
- Addiction (AREA)
- Vascular Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Otolaryngology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Indole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
SE REFIERE A UN COMPUESTO DE FORMULA I DONDE n ES 0-6; X ES CH2, CH2CH2, O; Z ES CHR2, NR2; R1 Y R2 SON H, ALQUILO C1-C6, ARILO, HETEROARILO, ENTRE OTROS; CON LA CONDICION QUE EL GRUPO HETEROARILO NO CONTENGA MAS DE UN ATOMO DE OXIGENO O AZUFRE EN EL ANILLO. UN COMPUESTO PREFERIDO ES ACIDO-2-(ENDO)-AMINO-BICICLO[2.2.1]HEPTANO-2-(EXO)-6-(EXO)-DICARBOXILICO, ENTRE OTROS. TAMBIEN SE REFIERE A UNA COMPOSICION QUE COMPRENDE ADEMAS UN INHIBIDOR DE LA RECAPTACION DE SEROTONINA O UN LIGANDO DEL RECEPTOR DE SEROTONINA-1A (5HT1A) TAL COMO SERTRALINA, FLUOXETINA, FLUVOXAMINA, PAROXETINA, CITALOPRAM, FENFLURAMINA Y FEMOXETINA. EL COMPUESTO I PUEDE SER UTIL PARA TRATAR TRASTORNOS NEUROLOGICOS Y PSIQUIATRICOSREFERS TO A COMPOUND OF FORMULA I WHERE n IS 0-6; X IS CH2, CH2CH2, O; Z IS CHR2, NR2; R1 AND R2 ARE H, C1-C6 ALKYL, ARYL, HETEROARYL, AMONG OTHERS; WITH THE CONDITION THAT THE HETEROARYL GROUP DOES NOT CONTAIN MORE THAN ONE OXYGEN OR SULFUR ATOM IN THE RING. A PREFERRED COMPOUND IS ACID-2- (ENDO) -AMINE-BICYCLE [2.2.1] HEPTANE-2- (EXO) -6- (EXO) -DICARBOXYL, AMONG OTHERS. IT ALSO REFERS TO A COMPOSITION THAT ALSO INCLUDES A SEROTONIN RECAPTATION INHIBITOR OR A SEROTONIN-1A (5HT1A) RECEPTOR BINDER SUCH AS SERTRALINE, FLUOXETINE, FLUVOXAMINE, PAROXETINE, PHENALFLOPRAMINE, PHENALFLOPRAMINE, AND FENALFLOPRAMINE. COMPOUND I MAY BE USEFUL TO TREAT NEUROLOGICAL AND PSYCHIATRIC DISORDERS
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7834698P | 1998-03-17 | 1998-03-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
PE20000339A1 true PE20000339A1 (en) | 2000-05-13 |
Family
ID=22143450
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PE1999000198A PE20000339A1 (en) | 1998-03-17 | 1999-03-12 | BICYCLE [2.2.1] HEPTANS AND RELATED COMPOUNDS |
Country Status (40)
Country | Link |
---|---|
US (1) | US6136861A (en) |
EP (1) | EP1064256B1 (en) |
JP (1) | JP3665567B2 (en) |
KR (1) | KR100372981B1 (en) |
CN (1) | CN1231461C (en) |
AP (1) | AP1116A (en) |
AR (1) | AR017236A1 (en) |
AT (1) | ATE272608T1 (en) |
AU (1) | AU753422B2 (en) |
BG (1) | BG104837A (en) |
BR (1) | BR9908850A (en) |
CA (1) | CA2321639C (en) |
CO (1) | CO5090835A1 (en) |
CZ (1) | CZ20003355A3 (en) |
DE (1) | DE69919142T2 (en) |
DZ (1) | DZ2745A1 (en) |
EA (1) | EA003946B1 (en) |
ES (1) | ES2224604T3 (en) |
GT (1) | GT199900040A (en) |
HR (1) | HRP20000611A2 (en) |
HU (1) | HUP0101031A3 (en) |
ID (1) | ID25651A (en) |
IL (1) | IL138342A0 (en) |
IS (1) | IS5592A (en) |
MA (1) | MA26614A1 (en) |
MY (1) | MY121047A (en) |
NO (1) | NO20004626L (en) |
NZ (1) | NZ506227A (en) |
OA (1) | OA11488A (en) |
PE (1) | PE20000339A1 (en) |
PL (1) | PL343278A1 (en) |
PT (1) | PT1064256E (en) |
SK (1) | SK13532000A3 (en) |
TN (1) | TNSN99039A1 (en) |
TR (1) | TR200002671T2 (en) |
TW (1) | TW509667B (en) |
UA (1) | UA53781C2 (en) |
WO (1) | WO1999047490A1 (en) |
YU (1) | YU53700A (en) |
ZA (1) | ZA992094B (en) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6555564B1 (en) * | 1999-03-04 | 2003-04-29 | The Board Of Trustees Of The University Of Illinois | Neuropharmacological treatments of sleep-related breathing disorders |
US6313159B1 (en) | 1999-08-20 | 2001-11-06 | Guilford Pharmaceuticals Inc. | Metabotropic glutamate receptor ligand derivatives as naaladase inhibitors |
UA73981C2 (en) * | 2000-03-10 | 2005-10-17 | Merck Patent Gmbh | (r)-(-)-2-[5-(4-fluorophenyl)-3-pyridylmethylaminomethyl]-chromane for treatment of extrapyramidal movement disorders (variants), pharmaceutical composition and kit |
JP2004532200A (en) * | 2001-03-15 | 2004-10-21 | サエジス ファーマシューティカルズ, インコーポレイテッド | Methods for restoring cognitive function after systemic stress |
US6689905B2 (en) | 2001-06-29 | 2004-02-10 | Wyeth | Stereoisomers of 3-aminotricyclo[2.2.1.0(2.6)]heptane-1,3-dicarboxylic acid |
US6750364B2 (en) | 2001-06-29 | 2004-06-15 | Wyeth | Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine as inhibitors of glutamate transport |
US6689904B2 (en) | 2001-06-29 | 2004-02-10 | Wyeth | Bridged tricyclic analogs of 2-(carboxycyclopropyl)glycine |
CA2458375A1 (en) | 2001-08-24 | 2003-03-06 | Pharmacia & Upjohn Company | Substituted-heteroaryl-7-aza¬2.2.1|bicycloheptanes for the treatment of disease |
US7232798B2 (en) * | 2001-11-13 | 2007-06-19 | Tran Loi H | Neuroprotection and neuroegenisis by administering cyclic prolyl glycine |
FR2872045B1 (en) * | 2004-06-28 | 2006-09-29 | Centre Nat Rech Scient Cnrse | MEDICAMENTS FOR THE SPECIFIC TREATMENT OF SYMPTOMS OF PARKINSON'S DISEASE |
TWI417095B (en) * | 2006-03-15 | 2013-12-01 | Janssen Pharmaceuticals Inc | 1,4-disubstituted 3-cyano-pyridone derivatives and their use as positive allosteric modulators of mglur2-receptors |
TW200845978A (en) * | 2007-03-07 | 2008-12-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-tetrahydropyran-phenyl)-pyridin-2-one derivatives |
TW200900065A (en) | 2007-03-07 | 2009-01-01 | Janssen Pharmaceutica Nv | 3-cyano-4-(4-pyridinyloxy-phenyl)-pyridin-2-one derivatives |
CA2698808A1 (en) | 2007-09-13 | 2009-03-19 | Concert Pharmaceuticals, Inc. | Synthesis of deuterated catechols and benzo[d][1,3] dioxoles and derivatives thereof |
EP2205565B1 (en) * | 2007-09-14 | 2013-04-17 | Janssen Pharmaceuticals, Inc. | 1,3-disubstituted-4-phenyl-1 h-pyridin-2-ones |
KR20100065191A (en) | 2007-09-14 | 2010-06-15 | 오르토-맥닐-얀센 파마슈티칼스 인코포레이티드 | 1,3-disubstituted 4-(aryl-x-phenyl)-1h-pyridin-2-ones |
SI2203439T1 (en) | 2007-09-14 | 2011-05-31 | Ortho Mcneil Janssen Pharm | 1',3'-disubstituted-4-phenyl-3,4,5,6-tetrahydro-2h, 1'h-y1, 4' bipyridinyl-2'-ones |
US8785486B2 (en) * | 2007-11-14 | 2014-07-22 | Janssen Pharmaceuticals, Inc. | Imidazo[1,2-A]pyridine derivatives and their use as positive allosteric modulators of mGluR2 receptors |
RU2510396C2 (en) | 2008-09-02 | 2014-03-27 | Янссен Фармасьютикалз, Инк. | 3-azabicyclo[3,1,0]hexyl derivatives as modulators of metabotropic glutamate receptors |
ES2466341T3 (en) | 2008-10-16 | 2014-06-10 | Janssen Pharmaceuticals, Inc. | Indole and benzomorpholine derivatives as modulators of metabotropic glutamate receptors |
EP2373649B1 (en) | 2008-11-28 | 2013-01-23 | Janssen Pharmaceuticals, Inc. | Indole and benzoxazine derivatives as modulators of metabotropic glutamate receptors |
MY153913A (en) | 2009-05-12 | 2015-04-15 | Janssen Pharmaceuticals Inc | 7-aryl-1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
EA020671B1 (en) | 2009-05-12 | 2014-12-30 | Янссен Фармасьютикалз, Инк. | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS |
CA2760741C (en) | 2009-05-12 | 2018-05-01 | Addex Pharma S.A. | 1,2,4-triazolo [4,3-a] pyridine derivatives and their use for the treatment or prevention of neurological and psychiatric disorders |
CA2814998C (en) | 2010-11-08 | 2019-10-29 | Janssen Pharmaceuticals, Inc. | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
PT2649069E (en) | 2010-11-08 | 2015-11-20 | Janssen Pharmaceuticals Inc | 1,2,4-triazolo[4,3-a]pyridine derivatives and their use as positive allosteric modulators of mglur2 receptors |
JP5852666B2 (en) | 2010-11-08 | 2016-02-03 | ジヤンセン・フアーマシユーチカルズ・インコーポレーテツド | 1,2,4-Triazolo [4,3-a] pyridine derivatives and their use as positive allosteric modulators of the mGluR2 receptor |
TWI520935B (en) | 2010-11-18 | 2016-02-11 | 美國禮來大藥廠 | 4-substituted-3-phenylsulfanylmethyl-bicyclo(3.1.0)hexane compounds as mglur 2/3 antagonists |
US9056844B2 (en) | 2010-11-18 | 2015-06-16 | Eli Lilly And Company | 4-substituted-3-benzyloxy-bicyclo[3.1.0]hexane compounds as mGluR 2/3 antagonists |
EP2970104B1 (en) | 2013-03-14 | 2019-04-24 | Zeno Royalties & Milestones, LLC | Bicyclic analgesic compounds |
JO3368B1 (en) | 2013-06-04 | 2019-03-13 | Janssen Pharmaceutica Nv | 6,7-DIHYDROPYRAZOLO[1,5-a]PYRAZIN-4(5H)-ONE COMPOUNDS AND THEIR USE AS NEGATIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
JO3367B1 (en) | 2013-09-06 | 2019-03-13 | Janssen Pharmaceutica Nv | 1,2,4-TRIAZOLO[4,3-a]PYRIDINE COMPOUNDS AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS |
KR102380609B1 (en) | 2013-12-12 | 2022-03-30 | 리커리엄 아이피 홀딩스, 엘엘씨 | Bicyclic alkyl compounds and synthesis |
PL3096790T3 (en) | 2014-01-21 | 2020-01-31 | Janssen Pharmaceutica, N.V. | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
ME03518B (en) | 2014-01-21 | 2020-04-20 | Janssen Pharmaceutica Nv | Combinations comprising positive allosteric modulators or orthosteric agonists of metabotropic glutamatergic receptor subtype 2 and their use |
JP6741343B2 (en) | 2014-03-07 | 2020-08-19 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Propellane derivatives and synthesis |
KR20170048588A (en) | 2014-09-17 | 2017-05-08 | 카리라 파마슈티컬스, 아이앤씨. | Bicyclic compounds |
WO2017160926A1 (en) * | 2016-03-16 | 2017-09-21 | Kalyra Pharmaceuticals, Inc. | Analgesic compounds |
CA3063729A1 (en) | 2017-05-15 | 2018-11-22 | Recurium Ip Holdings, Llc | Analgesic compounds |
EP3843768A4 (en) | 2018-05-15 | 2022-11-23 | Tran, Lloyd Hung Loi | Therapeutic agent composition and method of use, for treatment of mild cognitive impairment, depression, and psychological disorders |
KR102157141B1 (en) | 2018-11-27 | 2020-09-17 | 주식회사 파미니티 | Compositions containing and natural clematis mandshurica extracts for improving cognitive function |
KR102172916B1 (en) | 2018-12-07 | 2020-11-02 | 주식회사 파미니티 | Compositions containing silk peptide and natural extracts for improving cognitive function |
US11198908B2 (en) | 2019-06-17 | 2021-12-14 | Biorchestra Co., Ltd. | Method for diagnosis of Alzheimer's disease using microRNA |
US10844380B1 (en) | 2019-06-17 | 2020-11-24 | Biorchestra Co., Ltd. | Uses for prevention or treatment of brain diseases using microrna |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU707142B2 (en) * | 1994-06-03 | 1999-07-01 | David R. Elmaleh | Meta substituted arylalkylamines and therapeutic and diagnostic uses therefor |
PL182285B1 (en) * | 1994-08-12 | 2001-12-31 | Lilly Co Eli | Synthetic stimulating amino acids and methods of obtaining them |
GB9605429D0 (en) * | 1995-11-16 | 1996-05-15 | Lilly Co Eli | Excitatory amino acid receptor antagonists |
BR9611521A (en) * | 1995-11-16 | 1999-06-29 | Lilly Co Eli | Exciting amino acid receptor antagonists |
-
1999
- 1999-03-04 WO PCT/IB1999/000376 patent/WO1999047490A1/en not_active Application Discontinuation
- 1999-03-04 EP EP99905122A patent/EP1064256B1/en not_active Expired - Lifetime
- 1999-03-04 NZ NZ506227A patent/NZ506227A/en unknown
- 1999-03-04 KR KR10-2000-7010264A patent/KR100372981B1/en not_active IP Right Cessation
- 1999-03-04 IL IL13834299A patent/IL138342A0/en unknown
- 1999-03-04 BR BR9908850-9A patent/BR9908850A/en not_active Application Discontinuation
- 1999-03-04 DE DE69919142T patent/DE69919142T2/en not_active Expired - Fee Related
- 1999-03-04 JP JP2000536687A patent/JP3665567B2/en not_active Expired - Fee Related
- 1999-03-04 AT AT99905122T patent/ATE272608T1/en not_active IP Right Cessation
- 1999-03-04 CZ CZ20003355A patent/CZ20003355A3/en unknown
- 1999-03-04 SK SK1353-2000A patent/SK13532000A3/en unknown
- 1999-03-04 PT PT99905122T patent/PT1064256E/en unknown
- 1999-03-04 TR TR2000/02671T patent/TR200002671T2/en unknown
- 1999-03-04 ES ES99905122T patent/ES2224604T3/en not_active Expired - Lifetime
- 1999-03-04 CA CA002321639A patent/CA2321639C/en not_active Expired - Fee Related
- 1999-03-04 PL PL99343278A patent/PL343278A1/en unknown
- 1999-03-04 CN CNB998040401A patent/CN1231461C/en not_active Expired - Fee Related
- 1999-03-04 YU YU53700A patent/YU53700A/en unknown
- 1999-03-04 AU AU25409/99A patent/AU753422B2/en not_active Ceased
- 1999-03-04 ID IDW20001811A patent/ID25651A/en unknown
- 1999-03-04 EA EA200000842A patent/EA003946B1/en not_active IP Right Cessation
- 1999-03-04 HU HU0101031A patent/HUP0101031A3/en unknown
- 1999-03-04 US US09/380,727 patent/US6136861A/en not_active Expired - Fee Related
- 1999-03-10 AP APAP/P/1999/001482A patent/AP1116A/en active
- 1999-03-12 TW TW088103874A patent/TW509667B/en not_active IP Right Cessation
- 1999-03-12 PE PE1999000198A patent/PE20000339A1/en not_active Application Discontinuation
- 1999-03-15 MY MYPI99000966A patent/MY121047A/en unknown
- 1999-03-15 AR ARP990101118A patent/AR017236A1/en unknown
- 1999-03-16 ZA ZA9902094A patent/ZA992094B/en unknown
- 1999-03-16 TN TNTNSN99039A patent/TNSN99039A1/en unknown
- 1999-03-16 GT GT199900040A patent/GT199900040A/en unknown
- 1999-03-16 DZ DZ990046A patent/DZ2745A1/en active
- 1999-03-16 MA MA25498A patent/MA26614A1/en unknown
- 1999-03-17 CO CO99016567A patent/CO5090835A1/en unknown
- 1999-04-03 UA UA2000095327A patent/UA53781C2/en unknown
-
2000
- 2000-08-18 IS IS5592A patent/IS5592A/en unknown
- 2000-09-15 HR HR20000611A patent/HRP20000611A2/en not_active Application Discontinuation
- 2000-09-15 NO NO20004626A patent/NO20004626L/en not_active Application Discontinuation
- 2000-09-18 OA OA1200000258A patent/OA11488A/en unknown
- 2000-10-11 BG BG104837A patent/BG104837A/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
PE20000339A1 (en) | BICYCLE [2.2.1] HEPTANS AND RELATED COMPOUNDS | |
PE20041040A1 (en) | COMPOUNDS DERIVED FROM AMIDES AS INHIBITORS OF 11-BETA-HYDROXIESTEROID-DEHYDROXYGENASE TYPE 1 | |
ES2196344T3 (en) | DERIVATIVES OF SULFONAMIDE AND ITS USE IN THE TREATMENT OF CNS DISORDERS. | |
ECSP066968A (en) | METHYL-ARIL OR HETEROARIL-AMIDA SUBSTITUTED COMPOUNDS | |
PE20040458A1 (en) | PYRIDINES SUBSTITUTED WITH ANTI-ANGIOGENIC ACTIVITY | |
SV2006002103A (en) | ORTOSUSTITUTED ARIL- OR HETEROARILAMIDE COMPOUNDS REF. PC32242A | |
PA8610801A1 (en) | ARIL OR HETEROARIL AMIDA COMPOUNDS | |
ES2104259T3 (en) | PHENYLSULPHONAMIDES SUBSTITUTED AS SELECTIVE BETA3 AGONISTS FOR THE TREATMENT OF DIABETES AND OBESITY. | |
GT200000198A (en) | NEW BENZOIMIDAZOL USEFUL DERIVATIVES AS ANTIPROLIFERATIVE AGENTS. | |
UY27503A1 (en) | NEW DERIVATIVES OF PIPERAZINA | |
CO4950563A1 (en) | NEW COMPOUNDS | |
EA200300519A1 (en) | CONNECTIONS OF DERIVATIVES OF BENZOTHIOPHENE, THE METHOD OF THEIR RECEPTION AND APPLICATION | |
ES2176719T3 (en) | DERIVATIVES OF BENZOPIRANO THAT HAVE AN ANTAGONIST ACTION OF LEUCOTRIENS. | |
EA200501148A1 (en) | Pyridyloxymethyl and benzisoxazole azabicyclic derivatives | |
PE20020194A1 (en) | 2,3,7,8,9,10,11,12-OCTAHYDROAZEPINE [4,5-b] PYRANE [3,2-e) SUBSTITUTE INDEOLS | |
ATE263143T1 (en) | CYCLOPENTYLALKYLNITRILS AND THE USE OF CYCLOPENTYLALKYL DERIVATIVES AS FRAGRANCES | |
ES2152319T3 (en) | DERIVED FROM USEFUL BENZENE AGAINST ISCHEMIES. | |
PE44199A1 (en) | BENZO [E] ISOINDOLES AND BENZO [H] ISOQUINOLINES TRICICLICOS | |
ES2173895T3 (en) | VASCULAR HYPERTROPHY SUPPRESSOR. | |
AR025135A1 (en) | A PHARMACEUTICAL COMPOSITION, THE USE OF A NON-PEPTIDIC CYSTINE DERIVATIVE, AND NEW NON-PEPTIDIC CYSTINE DERIVATIVES | |
UY28618A1 (en) | NEW SUBSTITUTED INDEPENDES OF PIPERIDINE OR HERERODERIVED OF THE SAME | |
KR920002545A (en) | disinfectant | |
ES2108691T3 (en) | UV ABSORBENT COMPOUNDS AND COMPOSITIONS. | |
AR014950A1 (en) | DERIVATIVES OF PIPERACINO ANTAGONISTAS OF NEUROQUININA | |
ES2186605T3 (en) | PROCEDURE FOR THE SYNTHESIS OF 5-ALYLBENZODIOXOLS. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant, registration | ||
FD | Application declared void or lapsed |